The polymerase chain reaction with prior reverse transcription of RNA into cDNA was applied to hepatitis C virus RNA detection in human serum samples of different origin. In order to eliminate false negative results, the following steps were optimized: RNA extraction, reverse transcription, and oligonucleotide primer selection.
. . " . f for the major part of hepatitis non-A, non-B infecThe hepatitis C virus, a single stranded RNA virus tions (1 -5) . Its nucleic acid sequence was determined with some structural relations to the flavivirus family, from cDNA clones derived from the nucleic acid has been identified as the infectious agent responsible extracts of the plasma of an experimentally infected chimpanzee (1) . The natural modes of hepatitis C virus transmission are not yet completely understood (3, 6) . Since the introduction of the hepatitis B surface antigen assay to blood donor screening in 1972, however, it has been known that blood transfusions and parenterally administered human blood products (e. g. coagulation factors, or fresh frozen plasma) constitute a major route of "hepatitis non-A, non-B" transmission (7) .
The nucleic acid sequences of the first hepatitis C virus cDNA clones provided the basis for the construction of recombinant peptides representing putative hepatitis C virus proteins (4, 8) . Cloned hepatitis C virus peptides were employed in anti-hepatitis C virus enzyme immunoassays. Since 1989, such enzyme immunoassays have identified many clinical cases of "hepatitis non-A, non-B" as hepatitis C virus infections (4, 9, 10, 11) . Anti-hepatitis C virus antibody screening of blood using these enzyme immunoassays, helped to identify and sort out apparently healthy blood donors with anti-hepatitis C virus antibodies who otherwise might have transmitted the virus (11) .
At present, hepatitis C virus cannot be detected by cell culture techniques. Neither can the virus be demonstrated with certainty by electron microscopy. This may be due to the comparatively low particle numbers of the virus (100 -1000 χ 10 3 /1) in viraemic samples (12, 13) . For the same reason, other methods for the detection of specific nucleic acid sequences, such as dot blot hybridization (14) or luminescence-labelled direct hybridization (15) are not applicable to hepatitis C virus detection.
The polymerase chain reaction with prior reverse transcription of viral RNA into cDNA is at present the only method applicable to hepatitis C virus detection. The general potential of this method became evident very soon after the discovery of the hepatitis C virus, but rather different results were obtained with different primers and different RNA extraction methods (12, 16 -23) . Such divergent results of hepatitis C virus RNA detection are in part due to the fact that the various isolates of hepatitis C virus exhibit rather low RNA sequence homologies for the major part of the genome (1, 8, (24) (25) (26) (27) (28) (29) 45 ). However, the 5'-terminal non-coding region is highly conserved (21, 30, 31, 32) , thus providing a good target for the polymerase chain reaction. We compared oligonucleotide primers targeted at different sections of the genome, including the highly conserved 5'-terminal non-coding region (12, 17, 20) .
The method was optimized for the monitoring of patients and blood donors.
Materials and Methods

Sera
Five hundred thirty three (533) sera were assayed. They were obtained from Cardiac surgery patients whose anti-hepatitis C virus antibodies had been discovered by pre-operative serological screening (n = 2).
The sera were stored at -20 °C.
RNA preparation
The whole extraction process was performed in 1.5 ml plastic tubes (Eppendorf, Hamburg), and centrifugations were performed at 10500g and 6 °C, unless stated otherwise.
Guanidinium salt extraction
Serum (200 μΐ) was mixed with 600 μΐ 4 mol/1 guanidinium isothiocyanate, 25 mmol/1 sodium citrate pH 7.0, 5 g/1 N-lauroylsarcosine, 0.1 mol/1 mercaptoethanol in 1.5 ml tubes at room temperature by brief vortexing. Phenol equilibrated with 1 mol/1 Tris-Cl, pH 7.5 (600 μΐ) was added and the tubes were vortexed. A solution of baker's yeast RNA (type III, Sigma, Taufkirchen) (1.2 g/l, 2 μΐ) was added and mixed, followed by 100 μΐ chloroform. The tubes were briefly vortexed again, placed on ice for 15 minutes and centrifuged for 15 minutes. The upper aqueous phases (ca 750 μΐ) were transferred to new tubes and extracted with an equal volume of chloroform. The interphases, containing proteinaceous material, were completely left behind. The mixtures were again centrifuged as before, and the aqueous layers without interphases were transferred to new tubes and mixed with at least an equal volume (or up to two volumes) of ice cold isopropanol. The tubes were left overnight at -20 °C, then centrifuged for 20 minutes. The supernatants were carefully poured off.
The pellets were washed with 200 μΐ of aqueous ethanol, volume fraction 0.7. After decantation, the tubes were left open for 60 min at 40 °C in order to dry out before the pellets were redissolved in 10 μΐ aqua ad iniectabilia (RNase free). The solutions were frozen at -20 °C for storage or used directly for reverse transcription (modified according to I.e. (12) and (33) . Polyethylene glycol precipitation Serum (500 μΐ) diluted with 500 μΐ aqua ad iniectabilia, and 500 μΐ 300 g/1 polyethylene glycol, average M r 8000 (Serva, Heidelberg), in 0.1 mol/1 NaCl were added. After brief vortexing, the tubes were placed on ice for 60 minutes before centrifugation for 15 minutes. The superaatants were completely removed by aspiration, and the pellets dissolved in 300 μΐ Tris/ EDTA buffer (10 mmol/1 Tris-Cl pH 7.0, 1 mmol/1 EDTA). Following the addition of 40 μΐ 100 g/1 SDS, the mixtures were extracted with 300 μΐ phenol (equilibrated with 1 mol/1 Tris-Cl pH 7.5), then centrifuged for 10 min. The aqueous phases were transferred to new tubes and extracted with 300 μΐ chloroform. After 5 minutes centrifugation, the aqueous phases were transferred to tubes prefilled with 30 μΐ 3 mol/1 sodium acetate, pH 5.0. Glycogen stock solution (from mussels, 20 g/1, Boehringer, Mannheim) (1 μΐ) was added and the tubes were vortexed. Ice cold ethanol (1 ml) was added, the tubes were briefly vortexed again and left overnight at -65 °C. After centrifugation for 20 minutes, the superaatants were completely removed and the tubes were left open at room temperature for two minutes to allow the remaining ethanol to evaporate. The pellets were dissolved in 10 μΐ aqua ad iniectabilia and used directly or stored frozen at -20 °C (modified ace. to I.e. (18)).
Ultracentrifugation
Concentration of samples: 3.5 ml serum were diluted with 31.5 ml of autoclaved 0.2 mol/1 phosphate buffered saline, pH 7.5, and centrifuged for 3 hours at 100 000 g, 4 °C (Kontron T-2070 centrifuge, TFT 7038 rotor, 35000 min" 1 ). The pellet was dissolved in 650 μΐ guanidinium isothiocyanate solution and immediately processed as described above.
Simulated concentration from pooled samples: three 200 μΐ serum samples known to contain hepatitis C virus were mixed each with 3.8 ml serum from healthy blood donors and 31 ml phosphate-buffered saline. A 200 μΐ sample was taken from each of these dilutions. After centrifugation, 200 μΐ samples drawn from the upper and the lower zone of the supernatants, and the pellets were all extracted with guanidinium salt solution as described above. The RNA extracts were dissolved in 10 μΐ aqua ad iniectabilia. Samples (2 μΐ) of the RNA extracts were used to make dilution series (10°, ΙΟ 1 , ΙΟ 2
-fold). All dilution RNA solutions were subjected to reverse transcription with Moloney murine leukaemia virus reverse transcriptase and nested polymerase chain reaction with primers NCR 1 -NCR 4 (17). •S2 "fc « Oligonucleotide primers Syntheses were performed using phosphite technology on an automated synthesizer (Applied Biosystems, Pfungstadt). After cleavage of the protecting groups, the oligonucleotides were purified by gel electrophoresis on 18% polyacrylamide gels (34) . Properties of the oligonucleotides are listed in table 1.
Polymerase chain reaction
A 5 μΐ fraction of a completed Moloney murine leukaemia virus reverse transcriptase reaction mixture was transferred to a 0.75 ml thermocycler tube, using stuffed pipette tips to prevent carryover via aerosols. The total polymerase chain reaction mix was 50 μΐ, containing 50 mmol/1 KC1, 20 mmol/1 Tris-Cl pH 8.4, 1.5 mmol/1 MgCl 2 , 0.1 g/1 gelatin, 200 μηιοΐ/ΐ of each 2'-deoxynucleoside-5'-triphosphate, 0.4 μηιοΐ/l of both oligonucleotide primers and 2 units of Thermus aquaticus DNA polymerase (Perkin Elmer). When a single set of primers was used, 35 thermal cycles were performed. For the "nested" polymerase chain reaction, 35 cycles were performed, and an aliquot of the reaction mix was then transferred to new tubes for further amplification in another 30 thermal cycles. In order to prevent "amplificate carryover", we followed the guidelines given by Kwok (35) . The work was divided into three activities: Pre amplification, amplification, and post amplification; a separate room was reserved for each.
In order to exclude false positive results, parallel polymerase chain reactions were performed using cDNA and untranscribed RNA extracts. For negative controls we used the complete polymerase chain reaction mixes run in the same series of amplifications, but without cDNA; for positive controls we used cDNA samples obtained by reverse transcription of guanidinium salt RNA extracts of the serum of a viraemic hepatitis C patient.
Nested polymerase chain reaction
The incubation mixture of the first amplification reaction (1 μΐ) was transferred with a disposable glass capillary pipette (SiidLaborbedarf, Gauting) into a thermocycler tube containing 24 μΐ polymerase chain reaction mix as described for the first amplification, but with "nested" primers NCR 3 and NCR 4 instead of "outer" primers NCR 1 and NCR 2, or with J 1 and J 2 instead of ED 1 and ED 2. 30 thermal cycles were performed.
Temperature cycle conditions 1 minute 94 °C, 1 minute annealing temperature (see tab. 1), 1 minute 72 °C. In order to reduce the time intervals required for temperature adjustment, a thermocycler equipped with high capacity Peltier elements was used (Landgraf, Hannover). Typical heating and cooling rates were 2.7 -2.9 °C/s, permitting completion of 30 temperature cycles in 115 minutes.
Monitoring of amplificate carryover
Swab controls of all places involved in work with polymerase chain reaction were taken every two weeks by excessive scratching of the control area with plastic pipettes. The pipette tips were then cut off with single-use razor blades, placed in thermocycler tubes containing reaction mix for the polymerase chain reaction, and the nested polymerase chain reaction was performed with nested primers NCR 1 -NCR 4. Possible aerosol transfer of amplificates was monitored by placing open tubes on ice, containing a complete reaction mix for the polymerase chain reaction, for periods of up to four hours in many parts of the laboratory, and subsequent performance of the polymerase chain reaction. RNA extracts were subjected to the polymerase chain reaction in parallel with the samples which had been reverse transcribed into cDNA.
Amplificate analysis
Samples (8 μΐ), either from a 25 μΐ "nested" polymerase chain reaction, from a 100 μΐ polymerase chain reaction with thermostable reverse transcriptase, or from a 50 μΐ polymerase chain reaction with a single set of primers, were mixed with 3 μΐ 300 g/1 sucrose, 1 g/1 bromphenol blue, 1 g/1 xylene cyanol in 450 mmol/1 Tris borate, pH 8. 
Sequence determination of amplificates
Slices containing ethidium bromide-stained amplificates were excised from agarose electrophoresis gels, and the amplificates were purified by absorption to silica with "spin bind" sintered glass centrifuge columns (FMC Bioproducts, distributed by Biozym, Hameln) according to the manufacturer's protocol. The purified material was blunt-end ligated into M 13 plasmids, cloned, and sequenced according to I.e. (36), using 2'-deoxycytidine a-[ 
Anti-hepatitis C virus antibody detection
Anti-hepatitis C virus antibody screening was performed with a "2nd generation" enzyme immunoassay employing a combination of recombinant hepatitis C virus peptides (Abbott, Wies-baden) (11) . Positive test results were confirmed by parallel testing with two supplementary enzyme immunoassays employing structural and non-structural hepatitis C virus antigens, respectively (Abbott, Wiesbaden). When both supplementary assays were negative, the and hepatitis C virus antibody status was defined as negative, and the positive reaction in the screening assay was assumed to be false positive.
Determination of serum alanine aminotransferase activity
The optimized standard method of the German Society of Clinical Chemistry was used (37) .
Results
Comparison of different primer pairs (tab. 2)
Thirty six anti hepatitis C virus antibody positive sera (22 from hepatitis C patients, 14 from blood donors) were extracted by the guanidinium salt method, and RNA was reverse transcribed with Moloney murine leukaemia virus reverse transcriptase. Hepatitis C virus RNA was detected in 21 of these sera (all from hepatitis C patients). Nested polymerase chain reaction with primers NCR 1 -NCR 4 detected hepatitis C virus RNA in all of these 21 sera, the primer pair NCR I/NCR 2 alone detected RNA in 19 of the sera, the primer pair ED 1/ED2 in 16 sera, and nested polymerase chain reaction with ED I/ED 2 and J I/ J 2 in only 5 sera. The latter finding is due to the fact that primers J 1/J 2 were originally designed for detection of the Japanese strain of hepatitis C virus, not the European/American strains. They do not perfectly match the amplificate obtained with the primer pair EDI/ED 2.
Efficiency of different RNA extraction methods (tab. 3) Twenty two anti-hepatitis C virus antibody positive sera (13 from blood donors, 9 from hepatitis C patients) were extracted using three different methods (guanidinium salt, proteinase K, and polyethylene glycol precipitation). Ultracentrifugation prior to RNA extraction was performed in parallel. Seventeen anti-hepatitis C virus antibody-positive sera from haemophiliacs were extracted both with guanidinium salt and proteinase K/phenol. Extraction with guanidinium salt solution gave the best overall yield. Polyethylene glycol precipitation performed poorly.
Ultracentrifugation of large serum samples did not improve the overall performance of RNA extraction. The same pattern of positive and negative polymerase chain reaction results was obtained after direct extraction of 200 μΐ serum and after prior concentration of the virus particles from 3.5 ml serum by ultracentrifugation.
When the overnight alcohol precipitation step of RNA was shortened, the resulting material was of poor quality, resulting in co-amplification of many artefacts along with the desired amplificates. As judged from the amplificate electrophoresis patterns, the parallel extraction with one method of serum, citrate plasma and EDTA plasma from the same patient led to identical results (8 patients tested).
Three frozen sera from viraemic patients with chronic hepatitis C, which served as positive controls, were thawed on ten occasions in order to remove small samples for RNA extraction. Hepatitis C virus RNA was consistently detected in these samples by the combination: guanidinium salt extraction/reverse transcription/ nested polymerase chain reaction with primers NCR 1-NCR 4.
Reverse transcription with two different enzymes (tab. 4)
Sixteen anti-hepatitis C virus antibody-positive sera (7 from blood donors and 9 from hepatitis C patients) were extracted with guanidinium salt solution, then reverse transcribed in parallel with Moloney murine leukaemia virus reverse transcriptase and with recombinant thermostable reverse transcriptase derived from Thermus aquaticus (Perkin Elmer). Among the 7 blood donor sera used in this investigation, we included deliberately 4 sera in which hepatitis C virus RNA had previously been detected, so that the efficiency of the reverse transcriptases would be tested with sera of low viraemia. From 13 sera, including the 4 blood donor sera, cDNA was obtained with Moloney murine leukaemia virus reverse transcriptase, whereas recombinant thermostable reverse transcriptase yielded cDNA from only 7 patient sera and from no blood donor sera. cDNA was amplified by nested polymerase chain reaction with primers NCR 1-NCR 4. 
Discussion
The combination of RNA extraction, reverse transcription and subsequent polymerase chain reaction is presently the only sensitive method available for hepatitis C virus detection that permits the prediction of infectivity of patients and blood donors. We were able to demonstrate that stepwise optimization of this method can eliminate many false negative results.
Guanidinium salt solution was superior to other RNA extraction methods. Reverse transcription and subsequent cDNA amplification with nested oligonucleotide primers targeted to the S'-terminal non-coding region of the hepatitis C virus genome detected the virus more often than with other primers (21, 22) (tab. 2). These results suggest that some recently published data on the prevalence of hepatitis C virus in antihepatitis C virus antibody positive patients and haemophiliacs may harbour some false negatives, since they were obtained using sub-optimal RNA extraction methods and primers (12, 16, 20) . In order to accumulate comparable data from different laboratories about hepatitis C virus prevalence in large numbers of samples, evaluation and standardization of the RNA detection procedures is required, including especially RNA extraction, reverse transcription, selection of oligonucleotide primers, and thermocycle conditions.
Hepatitis C virus particles may be recovered even from very dilute solutions by Ultracentrifugation. Although this concentration step is not required when hepatitis C virus RNA is to be detected in single serum samples, Ultracentrifugation may be very useful in the screening of large numbers of serum samples for hepatitis C virus. All virus particles contributed to a serum pool by a single serum sample will be recovered from the pellet after Ultracentrifugation, in spite of the dilution effect caused by the pooling. This approach is especially efficient when only very few of the screened samples contain the hepatitis C virus, as should be the case with preselected anti-hepatitis C virus antibody-negative blood donors. Such a screening can close the diagnostic window between hepatitis C virus infection and anti-hepatitis C seroconversion. Hepatitis C virus detection in all blood donations, combined with antibody screening, should be made mandatory with the aim of preventing transfusionrelated hepatitis C virus transmissions.
We found markedly different proportions of virus carriers in three groups of anti-hepatitis C virus antibody positive people, namely hepatitis C patients, haemophiliacs and blood donors (tab. 5).
The rate of 90% hepatitis C virus carriers among "hepatitis non-A, non-B" patients both with acute and chronic disease reflects the strong tendency of the hepatitis C infection to become chronic. With this in mind, we should undertake every possible effort to prevent the iatrogenic transmission of this virus infection, e. g. via blood transfusions.
We examined sera from 19 haemophiliacs who had received multiple doses of human plasma products before the introduction of virus inactivation procedures. All of them had anti-hepatitis C virus antibodies, and 17 of them carried the hepatitis C virus. Plasma derived clotting factor is the most likely source of their hepatitis C infections (38, 39) . Another 3 haemophiliacs in our study had been treated exclusively with virus-inactivated plasma products. They had no anti-hepatitis C virus antibodies and were not viraemic (tabs. 5 and 6). These findings reflect both the usefulness of virus inactivation procedures and the fact that viraemic plasma donors have contributed and probably continue to contribute to human plasma pools.
Among 36 anti-hepatitis C virus antibody positive blood donors, we found only 11% (4 of 36) viraemic individuals (tab. 5). This observation suggests that their apparent well-being correlated with periods of aviraemia. However, these blood donors were preselected, because we require that our blood donors be anti-HBc negative.
Anti-HBc antibodies are regarded as a marker not only for hepatitis B, but rather as marker of increased susceptibility to other infections which may be transmitted by blood. There are reports in the literature of the detection of anti-hepatitis C virus antibodies in archivated sera from blood donors involved in transfusion-related "heaptitis non-A, non-B" transmission (40 -42) . These donors had not been prescreened for anti-HBc antibodies and must be regarded as chronic hepatitis C virus carriers from their history. Two other reports (43, 44) give data about anti-hepatitis C virus antibody status and hepatitis C virus detection in the sera of randomly selected blood donors in London and in Australia who had not been prescreened for anti-HBc antibodies. The proportion of hepatitis C virus carriers among the anti-hepatitis C virus antibody positive blood donors in these studies was higher than in our study. In a study on blood donors with elevated serum alanine aminotransferase (13) , ca. 8% of the donors were found to be hepatitis C virus carriers and 4% were anti-HBc antibodypositive. Anti-HBc screening prior to the admission of blood donors obviously helps to identify some hepatitis C virus carriers.
Elevated serum alanine aminotransferase in donated blood has previously served as a surrogate marker to hepatitis non-A, non-B in Germany. Even after introduction of the anti-hepatitis C virus antibody screening, serum alanine aminotransferase determination was continued in order to detect hepatitis C virus infections during the interval before seroconversion. We did not detect hepatitis C virus RNA in 450 blood donor sera with elevated alanine aminotransferase (above 25 U/l). Moreover, all the viraemic blood donors in our study did not have elevated serum alanine aminotransferase, nor had they ever had elevated serum alanine aminotransferase during their history as blood donors. If serum alanine aminotransferase activity in blood donors cannot detect hepatitis C infections, what is its purpose now?
The usefulness of the polymerase chain reaction, combined with efficient nucleic acid extraction, for the detection of hepatitis C virus has been demonstrated. The method can be adapted to screening procedures and will soon find many routine applications both in transfusion medicine and in general infectiology.
